JP2011508773A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011508773A5 JP2011508773A5 JP2010541427A JP2010541427A JP2011508773A5 JP 2011508773 A5 JP2011508773 A5 JP 2011508773A5 JP 2010541427 A JP2010541427 A JP 2010541427A JP 2010541427 A JP2010541427 A JP 2010541427A JP 2011508773 A5 JP2011508773 A5 JP 2011508773A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- animal
- composition according
- norc
- ufa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 21
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 8
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 8
- 230000003920 cognitive function Effects 0.000 claims 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 6
- 230000002708 enhancing Effects 0.000 claims 5
- ASUTZQLVASHGKV-JDFRZJQESA-N Galantamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
- 229930003270 Vitamin B Natural products 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000001149 cognitive Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 235000000381 ginkgo Nutrition 0.000 claims 2
- 235000019156 vitamin B Nutrition 0.000 claims 2
- 239000011720 vitamin B Substances 0.000 claims 2
- RBQOQRRFDPXAGN-UHFFFAOYSA-N 3-methyl-1-(5-oxohexyl)-7-propylpurine-2,6-dione Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 claims 1
- 229940062527 Alendronate Drugs 0.000 claims 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 229960004015 Calcitonin Drugs 0.000 claims 1
- 102400000113 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- 206010057668 Cognitive disease Diseases 0.000 claims 1
- 208000003282 Consciousness Disorders Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- ADEBPBSSDYVVLD-UHFFFAOYSA-N Donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 1
- 229960003980 Galantamine Drugs 0.000 claims 1
- 241000218628 Ginkgo Species 0.000 claims 1
- 235000011201 Ginkgo Nutrition 0.000 claims 1
- 240000002883 Ginkgo biloba Species 0.000 claims 1
- 235000008100 Ginkgo biloba Nutrition 0.000 claims 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline zwitterion Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 claims 1
- 229960003104 Ornithine Drugs 0.000 claims 1
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 claims 1
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 1
- 229960004622 Raloxifene Drugs 0.000 claims 1
- 229940089617 Risedronate Drugs 0.000 claims 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 1
- 206010039911 Seizure Diseases 0.000 claims 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 claims 1
- 230000000111 anti-oxidant Effects 0.000 claims 1
- 230000003078 antioxidant Effects 0.000 claims 1
- 229960003121 arginine Drugs 0.000 claims 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 230000037147 athletic performance Effects 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- 235000013477 citrulline Nutrition 0.000 claims 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 claims 1
- 229960003642 nicergoline Drugs 0.000 claims 1
- 239000002840 nitric oxide donor Substances 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 239000003075 phytoestrogen Substances 0.000 claims 1
- 229960002934 propentofylline Drugs 0.000 claims 1
- 229960000759 risedronic acid Drugs 0.000 claims 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims 1
- 229960003946 selegiline Drugs 0.000 claims 1
- 229960000744 vinpocetine Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1009708P | 2008-01-04 | 2008-01-04 | |
| US61/010,097 | 2008-01-04 | ||
| US13738208P | 2008-07-30 | 2008-07-30 | |
| US61/137,382 | 2008-07-30 | ||
| PCT/US2008/013870 WO2009088433A1 (fr) | 2008-01-04 | 2008-12-19 | Compositions comprenant des acides gras insaturés et des composés libérant de l'oxyde nitrique et leur utilisation pour améliorer des fonctions cognitives et apparentées |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011508773A JP2011508773A (ja) | 2011-03-17 |
| JP2011508773A5 true JP2011508773A5 (fr) | 2012-02-09 |
| JP5979816B2 JP5979816B2 (ja) | 2016-08-31 |
Family
ID=40853324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010541427A Active JP5979816B2 (ja) | 2008-01-04 | 2008-12-19 | 不飽和脂肪酸及び酸化窒素放出化合物を含む組成物、並びに認知機能及び関連の機能を高めるためのそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20100233304A1 (fr) |
| EP (2) | EP2224930B1 (fr) |
| JP (1) | JP5979816B2 (fr) |
| CN (2) | CN101909632A (fr) |
| AU (1) | AU2008347177B2 (fr) |
| BR (1) | BRPI0822238B8 (fr) |
| CA (2) | CA2709660C (fr) |
| ES (2) | ES2586757T3 (fr) |
| MX (1) | MX337760B (fr) |
| RU (1) | RU2500402C2 (fr) |
| WO (1) | WO2009088433A1 (fr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8252742B2 (en) * | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| EP1888510A4 (fr) | 2005-05-27 | 2013-01-16 | Univ North Carolina | Particules liberant de l'oxyde nitrique pour therapie a base d'oxyde nitrique et applications biomedicales |
| NO2194781T3 (fr) * | 2007-10-04 | 2018-07-21 | ||
| AU2013200758B2 (en) * | 2008-07-18 | 2014-06-12 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| AU2009270712B2 (en) * | 2008-07-18 | 2013-02-21 | Hill's Pet Nutrition, Inc. | Method for enhancing the quality of life of a senior animal |
| CN102711729B (zh) | 2009-08-21 | 2015-04-01 | 诺万公司 | 局部用凝胶 |
| EP2467173B8 (fr) | 2009-08-21 | 2019-06-19 | Novan, Inc. | Pansements, procédés d'utilisation de ceux-ci et procédés de formation de ceux-ci |
| CN103533933A (zh) * | 2009-09-11 | 2014-01-22 | 雀巢产品技术援助有限公司 | 用于增强动物认知和相关功能的组合物和方法 |
| ES2634034T5 (es) * | 2009-12-29 | 2020-09-18 | Nestle Sa | Composiciones nutricionales con copos de fruta que contienen ácido docosahexenoico |
| US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
| CN102552457A (zh) * | 2010-12-24 | 2012-07-11 | 漆又毛 | 一种氨基酸和提取物组合物的药物用途 |
| CN103442725A (zh) * | 2011-01-25 | 2013-12-11 | 雀巢产品技术援助有限公司 | 治疗、减轻或预防动物的视觉系统衰退的方法和组合物 |
| US20130324608A1 (en) * | 2011-02-18 | 2013-12-05 | Yuanlong Pan | Methods and compositions for treating, reducing or preventing damage to the nervous system of animals |
| WO2012118829A2 (fr) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Xérogels libérant de l'oxyde nitrique modifiés par des groupements s-nitrosothiols tertiaires et procédés d'utilisation associés |
| CN104066342A (zh) * | 2011-03-18 | 2014-09-24 | 雀巢产品技术援助有限公司 | 可用于改善年龄相关性疾病的组合物和方法 |
| AT511776B1 (de) * | 2011-07-26 | 2014-03-15 | Gonadosan Gmbh | Verwendung von citrullin und ein kombinationspräparat zur verbesserung der männlichen fertilität |
| US20130059028A1 (en) * | 2011-09-01 | 2013-03-07 | Julie Marie Foy | Compositions and Methods for Providing a Life-Stage-Appropriate Animal Diet |
| CN102600124B (zh) * | 2012-02-06 | 2014-03-26 | 单宝华 | Omega-3增强组合物及其应用 |
| WO2014069666A1 (fr) * | 2012-10-30 | 2014-05-08 | Kyowa Hakko Bio Co., Ltd. | Agent pour prévenir ou améliorer le déclin de la fonction cérébrale |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| CN103609752B (zh) * | 2013-12-02 | 2016-05-25 | 内蒙古伊利实业集团股份有限公司 | 一种改善脑部认知功能的组合物及其制备方法与应用 |
| JP2017502283A (ja) * | 2013-12-19 | 2017-01-19 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 高タンパク質食品の腐敗を決定するための方法 |
| WO2015160234A1 (fr) * | 2014-04-17 | 2015-10-22 | N.V. Nutricia | Composition d'amélioration de cerveau |
| AU2015329536A1 (en) * | 2014-10-10 | 2017-04-06 | Société des Produits Nestlé S.A. | Compositions and methods for enhancing mobility or activity or treating frailty |
| CA2964858C (fr) * | 2014-10-22 | 2023-10-24 | Raffaele Migliaccio | Association comprenant de la spiruline et du palmitoylethanolamide et/ou des sels ou des derives pharmaceutiquement acceptables de ceux-ci et leurs formulations, pour une utilisat ion dans la prevention et/ou le traitement d'etats d'hyperactivite des tissus |
| WO2016108946A1 (fr) * | 2014-12-29 | 2016-07-07 | Hill's Pet Nutrition, Inc. | Composition alimentaire et procédé d'utilisation |
| MX2017015973A (es) * | 2015-06-22 | 2018-04-20 | Nestec Sa | Composiciones y metodos para mejorar la neurogenesis en animales. |
| CN105602998A (zh) * | 2016-01-18 | 2016-05-25 | 青岛哈拿生物科技有限公司 | 一种水溶性天然一氧化氮的制作方法及应用 |
| CN114767870A (zh) * | 2016-05-27 | 2022-07-22 | 雀巢产品有限公司 | 用于治疗或预防移动性受损的营养组合物 |
| AU2017336291B2 (en) * | 2016-09-29 | 2023-01-12 | Société des Produits Nestlé S.A. | Omega 3 fatty acids, no releasing compound and vitamin B12 as neuroprotectant in patients with no dementia |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| CA3056422C (fr) * | 2017-03-18 | 2023-05-09 | Steven M. McGarrah | Aliment pour animaux de compagnie comprenant de l'acide cannabidiolique |
| JP7270546B2 (ja) * | 2017-04-11 | 2023-05-10 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 個体における認知的加齢を特定及び軽減するためのオメガ３脂肪酸及びビタミンｄレベル |
| JP7266581B2 (ja) | 2017-08-14 | 2023-04-28 | アクセラ・ヘルス・インコーポレイテッド | 肝疾患の治療のためのアミノ酸組成物 |
| EP3810123A1 (fr) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle |
| WO2022191184A1 (fr) * | 2021-03-08 | 2022-09-15 | 国立大学法人九州大学 | Agent d'amélioration de la sensibilité du récepteur de ghréline, composition d'amélioration de la sensibilité du récepteur de ghréline et procédé d'activation du récepteur de ghréline |
| EP4449875A1 (fr) | 2023-04-18 | 2024-10-23 | Mars, Incorporated | Composition destinée à être utilisée pour améliorer ou préserver la santé mentale chez les chiens |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2018A (en) * | 1841-03-26 | Joseph francis | ||
| US6294520B1 (en) † | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
| GB2268871A (en) * | 1992-07-04 | 1994-01-26 | Bio Nutritional Health Service | Composition for use as a food or food supplement |
| IT1264987B1 (it) * | 1993-12-14 | 1996-10-17 | Prospa Bv | Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono |
| JPH11501301A (ja) † | 1995-02-23 | 1999-02-02 | ノバルティス・ニュートリション・アクチエンゲゼルシャフト | アミノ酸組成物および臨床的栄養補給におけるその使用 |
| CA2185983C (fr) * | 1996-09-19 | 2004-04-13 | Wie-Jong Kwak | Methode pour extraire des ingredients biologiquement actifs a partir d'une combinaison de plantes medecinales et les purifier; composition de l'extrait |
| US5874471A (en) * | 1997-02-27 | 1999-02-23 | Waugh; William Howard | Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection |
| ATE408402T1 (de) * | 1999-06-14 | 2008-10-15 | Ford Henry Health System | Stickstoffmonoxid-donoren zum induzieren von neurogenese |
| US7135498B1 (en) * | 1999-06-14 | 2006-11-14 | Henry Ford Health System | Nitric oxide donors for inducing neurogenesis |
| JP4669095B2 (ja) † | 1999-07-19 | 2011-04-13 | 太陽化学株式会社 | ペットの問題行動抑制組成物 |
| WO2007115282A2 (fr) * | 2006-04-03 | 2007-10-11 | Accera, Inc. | Utilisation de composés cétogènes pour le traitement des troubles cognitifs liés à l'âge |
| US20050002992A1 (en) † | 2003-06-17 | 2005-01-06 | Mccleary Edward Larry | Foods, beverages, condiments, spices and salad dressings with specialized supplements |
| US20040043013A1 (en) * | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
| WO2002076445A1 (fr) | 2001-03-23 | 2002-10-03 | Ajinomoto Co., Inc. | Agents utilises pour lutter contre les maladies provoquees par le stress et medicaments associes |
| US6964969B2 (en) * | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
| US20060014773A1 (en) * | 2001-04-19 | 2006-01-19 | Mccleary Edward L | Mental agility lozenge, edible strip, food or drink |
| DE10131516B4 (de) † | 2001-07-02 | 2004-05-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Steuereinheit zur Flussregulierung |
| WO2003032804A2 (fr) * | 2001-10-12 | 2003-04-24 | Cornell Research Foundation, Inc. | Methode permettant d'inverser ou d'empecher la senescence vasculaire prematuree |
| NL1019368C2 (nl) † | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
| US7514107B2 (en) * | 2002-03-21 | 2009-04-07 | Mars, Incorporated | Treatment of diseases involving defective gap junctional communication |
| US20040001817A1 (en) † | 2002-05-14 | 2004-01-01 | Giampapa Vincent C. | Anti-aging nutritional supplement |
| US20040087490A1 (en) * | 2002-09-20 | 2004-05-06 | Troup John P. | Nutritional compositions |
| CA2516142A1 (fr) † | 2003-03-18 | 2004-09-30 | Novartis Ag | Compositions comprenant des acides gras et des acides amines |
| DK1641351T3 (da) † | 2003-07-03 | 2014-08-25 | Hills Pet Nutrition Inc | Sammensætninger og fremgangsmåder til at formindske aldersrelateret forringelse af mental aktivitet hos familiedyr |
| US6951658B1 (en) † | 2003-07-08 | 2005-10-04 | Pearson Research & Development Limited | Emu-based compositions for mental well-being and method of use |
| US20060280776A1 (en) * | 2003-09-02 | 2006-12-14 | Masafumi Koide | Diet food |
| CN1898370A (zh) † | 2003-12-22 | 2007-01-17 | 湧永制药株式会社 | 油脂组合物 |
| US20060002985A1 (en) † | 2004-07-02 | 2006-01-05 | Zicker Steven C | Compositions and methods for decreasing age-related deterioration in mental activities in companion animals |
| EP1634599A1 (fr) * | 2004-08-20 | 2006-03-15 | N.V. Nutricia | Aliment infantile à activité immunostimulatrice |
| BRPI0519642A8 (pt) | 2004-12-29 | 2017-10-03 | Hill´S Pet Nutrition Inc | Método para inibir um declínio em aprendizagem e/ou memória, kit apropriado para administrar um ou mais antioxidantes a um animal, meio para transmitir informação, e, uso de uma composição |
| EP1830629A4 (fr) † | 2004-12-30 | 2008-08-27 | Hills Pet Nutrition Inc | Methodes permettant d'ameliorer la qualite de vie d'un animal age |
| AU2005321817A1 (en) | 2004-12-30 | 2006-07-06 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a growing animal |
| US8324276B2 (en) * | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
| CN1810257A (zh) * | 2005-05-26 | 2006-08-02 | 钟健琳 | 活脑素口服液 |
| US20100049583A1 (en) | 2005-06-30 | 2010-02-25 | Koninklijke Philips Electronics, N.V. | Method and system for selection of information |
| JP2009502745A (ja) | 2005-07-08 | 2009-01-29 | マーテック バイオサイエンシーズ コーポレーション | 認知症および前認知症に関連した状態を治療するための多価不飽和脂肪酸 |
| WO2007022991A1 (fr) * | 2005-08-26 | 2007-03-01 | Nestec S.A. | Compositions et methodes destinees a ameliorer l'integrite vasculaire fonctionnelle et la survie cellulaire et a reduire l'apoptose pendant une ischemie ou apres un episode ischemique dans le cerveau |
| AU2006299665B2 (en) * | 2005-09-30 | 2012-12-13 | Nestec S.A. | Methods and compositions for improving cognitive function |
| EP1955698B1 (fr) † | 2005-12-02 | 2013-10-30 | Mochida Pharmaceutical Co., Ltd. | Agent preventif/therapeutique contre la demence d'alzheimer |
| EP1800675B1 (fr) † | 2005-12-23 | 2011-05-18 | N.V. Nutricia | Composition comprenant des acides gras polyinsaturés, des protéines, du manganèse et/ou du molybdène et des nucléosides/nucléotides, pour traiter la démence. |
| NO2194781T3 (fr) | 2007-10-04 | 2018-07-21 | ||
| EP2939314B1 (fr) | 2012-12-31 | 2018-08-29 | Mitel Networks Corporation | Adaptateur d'interface |
-
2008
- 2008-12-19 BR BRPI0822238A patent/BRPI0822238B8/pt active IP Right Grant
- 2008-12-19 CN CN200880123505XA patent/CN101909632A/zh active Pending
- 2008-12-19 ES ES08869735.4T patent/ES2586757T3/es active Active
- 2008-12-19 CA CA2709660A patent/CA2709660C/fr active Active
- 2008-12-19 EP EP08869735.4A patent/EP2224930B1/fr active Active
- 2008-12-19 EP EP16163261.7A patent/EP3058942B2/fr active Active
- 2008-12-19 CN CN201510779748.0A patent/CN105267969A/zh active Pending
- 2008-12-19 MX MX2010007438A patent/MX337760B/es active IP Right Grant
- 2008-12-19 US US12/734,013 patent/US20100233304A1/en not_active Abandoned
- 2008-12-19 RU RU2010132637/15A patent/RU2500402C2/ru active
- 2008-12-19 AU AU2008347177A patent/AU2008347177B2/en active Active
- 2008-12-19 JP JP2010541427A patent/JP5979816B2/ja active Active
- 2008-12-19 WO PCT/US2008/013870 patent/WO2009088433A1/fr active Application Filing
- 2008-12-19 ES ES16163261T patent/ES2773928T5/es active Active
- 2008-12-19 CA CA2994586A patent/CA2994586C/fr active Active
-
2017
- 2017-02-23 US US15/440,702 patent/US10111911B2/en active Active
-
2018
- 2018-10-03 US US16/150,979 patent/US10973859B2/en active Active
-
2021
- 2021-03-19 US US17/206,851 patent/US11951137B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011508773A5 (fr) | ||
| DE60217103T2 (de) | Verstärkte wirkung mehrfach ungesättigter fettsäuren | |
| RU2010132637A (ru) | Композиции, включающие ненасыщенные жирные кислоты и соединения, высбождающие оксид азота, и их применение для усиления когнитивной функции и связанных с ней функцией | |
| Rosenstein et al. | Pilot study of dietary fatty acid supplementation in the treatment of adult periodontitis | |
| RU2010117221A (ru) | Композиции и способы усиления когнитивной функции | |
| JP2015143248A5 (fr) | ||
| BRPI0516718A (pt) | forma de dosagem de ibuprofeno de liberação modificada | |
| JP2014515011A5 (fr) | ||
| WO2005115341A3 (fr) | Microparticules pour administration orale | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| BRPI0813320A2 (pt) | Fração lipídica, e, produto farmacêutico ou nutricional | |
| JP2014514248A5 (fr) | ||
| Zarif Najafi et al. | Comparison of the effects of preemptive acetaminophen, ibuprofen, and meloxicam on pain after separator placement: a randomized clinical trial | |
| RU2013146517A (ru) | Композиции и способы, пригодные для облегчения возрастных заболеваний | |
| JP2007238598A5 (fr) | ||
| JP2015510888A5 (fr) | ||
| MA38576A1 (fr) | Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières | |
| FR2902007B1 (fr) | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques | |
| CA2705936C (fr) | Utilisation d'acides gras omega-3 pour le soulagement de la douleur | |
| HRP20110453T1 (hr) | Sastav peleta lipoične kiseline | |
| JPH0788301B2 (ja) | 記憶喪失の治療または予防用組成物 | |
| Kim et al. | Supplementation with Angelica keiskei inhibits expression of inflammatory mediators in the gastric mucosa of Helicobacter pylori–infected mice | |
| JP2017186335A (ja) | アミロイドβ凝集阻害剤 | |
| ATE443515T1 (de) | Omega-3-fettsäuren und omega-6-fettsäuren enthaltende zusammensetzung | |
| WO2012075093A3 (fr) | Formes galéniques topiques utilisables en vue de l'administration d'acides gras oméga-3 |